{"id":"r-minichop","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL89731","moleculeType":"Small molecule","molecularWeight":"159.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R-miniCHOP reduces the doses of conventional CHOP chemotherapy agents while maintaining the anti-CD20 monoclonal antibody rituximab, aiming to preserve efficacy against B-cell lymphomas while decreasing treatment-related morbidity and mortality. This approach is particularly relevant for elderly or frail patients who may not tolerate standard-dose R-CHOP.","oneSentence":"R-miniCHOP is a reduced-intensity chemotherapy regimen combining rituximab with a modified CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) backbone designed to treat lymphomas with lower toxicity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:52:08.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma in elderly or frail patients"}]},"trialDetails":[{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT04974216","phase":"PHASE2","title":"Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-12-20","conditions":"DLBCL","enrollment":71},{"nctId":"NCT05820841","phase":"PHASE3","title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-06-07","conditions":"Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":330},{"nctId":"NCT05179733","phase":"PHASE3","title":"The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-03-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":280},{"nctId":"NCT05809180","phase":"NA","title":"Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-04","conditions":"Diffuse Large B Cell Lymphoma","enrollment":35},{"nctId":"NCT04442412","phase":"PHASE3","title":"Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-03-23","conditions":"Diffuse Large B-Cell Lymphoma, Elderly Patients","enrollment":430},{"nctId":"NCT02128061","phase":"PHASE3","title":"Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2014-08","conditions":"Diffuse Large B Cell Lymphoma","enrollment":250},{"nctId":"NCT02767674","phase":"PHASE3","title":"Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":258}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-miniCHOP","genericName":"R-miniCHOP","companyName":"Universität des Saarlandes","companyId":"universit-t-des-saarlandes","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-miniCHOP is a regimen used in the first-line treatment of elderly patients with diffuse large B-cell lymphoma. It consists of the combination of rituximab, a monoclonal antibody, with the chemotherapy drugs cyclophosphamide, doxorubicin, vincristine, and prednisone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}